ASMI is a cell-permeable, non-toxic, biocompatible, photostable, positively charged, mitochondria targeting styryl-methylpyridinium based compound that acts as a rapid, cysteine selective, sensitive, and ratiometric (F 518 /F 452 nm) fluorescent turn-on probe (0.5 - 40 μM of [Cys]). Under physiological conditions, cysteine thiol reacts with the ASMI acrylate moiety in a time-dependent manner, and induces a facile intramolecular cyclization to release fluorogenic oxystyryl methylpyridinium. ASMI displays high selectivity over other biothiols (Kobs = 0.75, 0.038, 0.011 & 0.012 min -1 for Cys, Hcy, GSH & Na 2 S, respectively) and with no interference from other biologically relevant amino acids, essential metal ions, and anions, including Na2S. Shown to monitor mitochondrial Cys levels in HeLa cells and in deep tissues (150 μm of penetration depth) by two-photon excited fluorescence microscopy.
| Molecular Weight | 393.22 |
| Formula | C17H16NIO2 |
| CAS Number | 1850419-05-4 |
| Solubility (25°C) | DMSO: 10 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[5] Jeremy Loftice, et al. Biomechanics of the elbow in sports
| Related Products |
|---|
| Izeltabart
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C to synthesize IMGC936, an Antibody-drug Conjugate with strong anti-cancer activity. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models. |
| Cofetuzumab
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. |
| Crizanlizumab
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs). |
| M3554 (anti-GD2 ADC)
M3554 is a novel anti-GD2 ADC designed based on humanized ch14.18 anti-GD2 antibody. M3554 has anti-tumor activity. |
| OGT2115
OGT2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT2115 has anti-angiogenic properties (IC50 = 1 μM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
